Conatumumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Conatumumab?
Monoclonal antibody
Type Whole antibody
Source Human
Target TRAIL-R2 (CD262)
Identifiers
CAS Registry Number 896731-82-1 N
ATC code None
UNII 1P48L61KM0 YesY
KEGG D09329 YesY
Synonyms anti-TRAIL receptor 2 monoclonal antibody, AMG 655
Chemical data
Formula C6466H10006N1730O2024S40
Molecular mass 145.65 kDa
 N (what is this?)  (verify)

Conatumumab (originally AMG 655) is a monoclonal antibody developed for the treatment of cancer. it is a fully human monoclonal agonist antibody directed against the extracellular domain of human TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) receptor 2 (TR-2, death receptor 5) with potential antineoplastic activity. Conatumumab mimics the activity of native TRAIL, binding to and activating TR-2, thereby activating caspase cascades and inducing tumor cell apoptosis. TR-2 is expressed by a variety of solid tumors and cancers of hematopoietic origin.[1][2]

The drug was developed by Amgen Inc.

Clinical trials[edit]

It will be included in the forthcoming I-SPY2 breast cancer trial.[3]

References[edit]

  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council – Conatumumab, American Medical Association.
  2. ^ National Cancer Institute: Definition of conatumomab
  3. ^ http://www.reuters.com/article/idUSN1612347120100317 "Breast cancer study aims to speed drugs, cooperation" March 2010